In May, funds managed by Apax Partners & Cie, together with the quoted investment vehicle Altamir, provided FFr 6 million (ecu 900,000) of follow-on venture backing for Hybrigenics.
The young company specialises in the identification of new pharmaceutical agents with potential therapeutic applications in the treatment of cancer and infectious diseases. Hybrigenics recently formed a strategic alliance with the Institut Pasteur, where its laboratories are based. It also works closely with France national research agency CNRL and Inserm.
Dr Laurent Ganem of Apax described Hybrigenics as one of the most promising projects in the international drug discovery domain.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: